Fate Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Fate Therapeutics

04/11/2021 21:56

* Fate Therapeutics Inc  FATE.OQ  reported a quarterly adjusted
loss of 45 cents​​ per share for the quarter ended in September.
The mean expectation of seventeen analysts for the quarter was
for a loss of 58 cents per share.
* Revenue rose 88.2% to $14.23 million from a year ago; 
analysts expected $7.89 million. 
* Fate Therapeutics Inc's reported EPS for the quarter was a
loss of 45 cents​.
* The mean earnings estimate of analysts had fallen by
about 1.9% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Fate Therapeutics Inc shares had risen by 1.9% this
quarter and lost 33.6% so far this year.
* The company reported a quarterly loss of $43.31 million.
* Wall Street's median 12-month price target for Fate
Therapeutics Inc is $113.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 14 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 4 at 09:56 p.m.
 ​All figures in US dollars unless otherwise stated